Seizure risk in patients with attention-deficit-hyperactivity disorder treated with atomoxetine

Joachim F. Wernicke, Karen Chilcott Holdridge, Ling Jin, Timothy Edison, Shuyu Zhang, Mark E. Bangs, Albert J. Allen, Susan Ball, David Dunn

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

The comorbidity of seizures, epilepsy, and attention-deficit-hyperactivity disorder (ADHD) prompted the examination of whether atomoxetine use for ADHD is associated with an increased risk of seizures. Seizures and seizure-related symptoms were reviewed from two independent Eli Lilly and Company databases: the atomoxetine clinical trials database and the atomoxetine postmarketing spontaneous adverse event database. Review of clinical trial data indicated that the crude incidence rates of seizure adverse events were between 0.1 and 0.2%, and were not significantly different between atomoxetine, placebo, and methylphenidate. Only 2% of the postmarketing spontaneous reports of seizure events were classified as having no clear contributing or confounding factors, and the reporting rate (8 per 100 000 patients exposed) was within the expected range of population-based incidence. Although children with ADHD are increasingly recognized as being at an elevated risk for seizures, treatment of ADHD symptoms with atomoxetine does not appear to elevate this risk further. The shared vulnerability between ADHD and seizure activity should be taken into account when making treatment decisions for populations of children with epilepsy and children with ADHD.

Original languageEnglish
Pages (from-to)498-502
Number of pages5
JournalDevelopmental Medicine and Child Neurology
Volume49
Issue number7
DOIs
StatePublished - Jul 2007

Fingerprint

Attention Deficit Disorder with Hyperactivity
Seizures
Databases
Epilepsy
Clinical Trials
Methylphenidate
Atomoxetine Hydrochloride
Incidence
Population
Comorbidity
Decision Making
Placebos
Therapeutics

ASJC Scopus subject areas

  • Clinical Neurology
  • Pediatrics, Perinatology, and Child Health
  • Neuroscience(all)

Cite this

Seizure risk in patients with attention-deficit-hyperactivity disorder treated with atomoxetine. / Wernicke, Joachim F.; Holdridge, Karen Chilcott; Jin, Ling; Edison, Timothy; Zhang, Shuyu; Bangs, Mark E.; Allen, Albert J.; Ball, Susan; Dunn, David.

In: Developmental Medicine and Child Neurology, Vol. 49, No. 7, 07.2007, p. 498-502.

Research output: Contribution to journalArticle

Wernicke, Joachim F. ; Holdridge, Karen Chilcott ; Jin, Ling ; Edison, Timothy ; Zhang, Shuyu ; Bangs, Mark E. ; Allen, Albert J. ; Ball, Susan ; Dunn, David. / Seizure risk in patients with attention-deficit-hyperactivity disorder treated with atomoxetine. In: Developmental Medicine and Child Neurology. 2007 ; Vol. 49, No. 7. pp. 498-502.
@article{2fd6c2b273d94464847c4a1ae4519f98,
title = "Seizure risk in patients with attention-deficit-hyperactivity disorder treated with atomoxetine",
abstract = "The comorbidity of seizures, epilepsy, and attention-deficit-hyperactivity disorder (ADHD) prompted the examination of whether atomoxetine use for ADHD is associated with an increased risk of seizures. Seizures and seizure-related symptoms were reviewed from two independent Eli Lilly and Company databases: the atomoxetine clinical trials database and the atomoxetine postmarketing spontaneous adverse event database. Review of clinical trial data indicated that the crude incidence rates of seizure adverse events were between 0.1 and 0.2{\%}, and were not significantly different between atomoxetine, placebo, and methylphenidate. Only 2{\%} of the postmarketing spontaneous reports of seizure events were classified as having no clear contributing or confounding factors, and the reporting rate (8 per 100 000 patients exposed) was within the expected range of population-based incidence. Although children with ADHD are increasingly recognized as being at an elevated risk for seizures, treatment of ADHD symptoms with atomoxetine does not appear to elevate this risk further. The shared vulnerability between ADHD and seizure activity should be taken into account when making treatment decisions for populations of children with epilepsy and children with ADHD.",
author = "Wernicke, {Joachim F.} and Holdridge, {Karen Chilcott} and Ling Jin and Timothy Edison and Shuyu Zhang and Bangs, {Mark E.} and Allen, {Albert J.} and Susan Ball and David Dunn",
year = "2007",
month = "7",
doi = "10.1111/j.1469-8749.2007.00498.x",
language = "English",
volume = "49",
pages = "498--502",
journal = "Developmental Medicine and Child Neurology",
issn = "0012-1622",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - Seizure risk in patients with attention-deficit-hyperactivity disorder treated with atomoxetine

AU - Wernicke, Joachim F.

AU - Holdridge, Karen Chilcott

AU - Jin, Ling

AU - Edison, Timothy

AU - Zhang, Shuyu

AU - Bangs, Mark E.

AU - Allen, Albert J.

AU - Ball, Susan

AU - Dunn, David

PY - 2007/7

Y1 - 2007/7

N2 - The comorbidity of seizures, epilepsy, and attention-deficit-hyperactivity disorder (ADHD) prompted the examination of whether atomoxetine use for ADHD is associated with an increased risk of seizures. Seizures and seizure-related symptoms were reviewed from two independent Eli Lilly and Company databases: the atomoxetine clinical trials database and the atomoxetine postmarketing spontaneous adverse event database. Review of clinical trial data indicated that the crude incidence rates of seizure adverse events were between 0.1 and 0.2%, and were not significantly different between atomoxetine, placebo, and methylphenidate. Only 2% of the postmarketing spontaneous reports of seizure events were classified as having no clear contributing or confounding factors, and the reporting rate (8 per 100 000 patients exposed) was within the expected range of population-based incidence. Although children with ADHD are increasingly recognized as being at an elevated risk for seizures, treatment of ADHD symptoms with atomoxetine does not appear to elevate this risk further. The shared vulnerability between ADHD and seizure activity should be taken into account when making treatment decisions for populations of children with epilepsy and children with ADHD.

AB - The comorbidity of seizures, epilepsy, and attention-deficit-hyperactivity disorder (ADHD) prompted the examination of whether atomoxetine use for ADHD is associated with an increased risk of seizures. Seizures and seizure-related symptoms were reviewed from two independent Eli Lilly and Company databases: the atomoxetine clinical trials database and the atomoxetine postmarketing spontaneous adverse event database. Review of clinical trial data indicated that the crude incidence rates of seizure adverse events were between 0.1 and 0.2%, and were not significantly different between atomoxetine, placebo, and methylphenidate. Only 2% of the postmarketing spontaneous reports of seizure events were classified as having no clear contributing or confounding factors, and the reporting rate (8 per 100 000 patients exposed) was within the expected range of population-based incidence. Although children with ADHD are increasingly recognized as being at an elevated risk for seizures, treatment of ADHD symptoms with atomoxetine does not appear to elevate this risk further. The shared vulnerability between ADHD and seizure activity should be taken into account when making treatment decisions for populations of children with epilepsy and children with ADHD.

UR - http://www.scopus.com/inward/record.url?scp=34347401245&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34347401245&partnerID=8YFLogxK

U2 - 10.1111/j.1469-8749.2007.00498.x

DO - 10.1111/j.1469-8749.2007.00498.x

M3 - Article

VL - 49

SP - 498

EP - 502

JO - Developmental Medicine and Child Neurology

JF - Developmental Medicine and Child Neurology

SN - 0012-1622

IS - 7

ER -